Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Kinross Gold Corporation (KGC) vs 10X Genomics Inc (TXG) Price & Performance

Kinross Gold CorporationTrade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

Kinross Gold Corporation vs 10X Genomics Inc — how do they compare? Kinross Gold Corporation trades at $27.53 (market cap $32.29B), while 10X Genomics Inc trades at $57.31 (market cap $7.61B). The key difference: Kinross Gold Corporation is far larger — about 4.2× 10X Genomics Inc's market cap, and Kinross Gold Corporation pays a 0.59% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.

KGCTXG
Market Cap
$32.29B$7.61B
Sector
Basic MaterialsHealth
52-Week High
$38.06$58.57
52-Week Low
$18.70$11.34
Enterprise Value
$30.37B$7.14B
Dividend Yield
0.59%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Kinross Gold Corporation

Kinross Gold (KGC) trades at $27.59, up 0.69% with strong fundamental momentum. The company demonstrates robust earnings growth with three consecutive quarterly beats and impressive profitability metrics including 37.52% net margin and 36.95% ROE. Recent S&P upgrade to 'BBB' and positive project developments at Lobo-Marte support the bullish analyst consensus.

Outlook remains positive with 29 analysts showing 58.6% buy ratings and $37.20 consensus target, representing 35% upside. Key risks include gold price volatility and execution challenges at new projects. Strong free cash flow generation and disciplined capital allocation support continued shareholder returns.

10X Genomics Inc

TXG (10x Genomics) trades at $56.95, down 2.77% on the day. The stock exhibits bullish technical signals with strong moving averages, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and a narrowing net loss margin from -41.23% in 2023 to -12.18% in 2026. Recent news highlights collaborations with Cleveland Clinic and acquisition of Proteintech Genomics, expanding multiomics capabilities.

Outlook: Growth potential exists through market expansion and innovation, but risks include persistent unprofitability and high valuation multiples. Analyst sentiment is mixed with a $46 consensus target below current price, indicating caution despite recent operational improvements.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Kinross Gold Corporation

Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.

Read more on KGC

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG